drugset
drugset / Trial / NCT04915989

Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals

NCT04915989 ↗

Phase 1 Completed 30 enrolled Genexine, Inc.
NaSingle-groupOpen-labelPrevention

Summary

The objective of the study is to demonstrate safety and immunogenicity of COVID-19 preventive DNA vaccine in elderly individuals.

Timeline

Start
2021-02-16
Primary completion
2022-04-01
Completion
2022-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GX-19N Vaccine — Intramuscular

Indications

COVID-19